Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is 1 of the best multibagger stocks to put successful according to billionaires. On February 5, Arrowhead Pharmaceuticals achieved a strategical turning constituent successful FQ1 2026, transitioning into a commercial-stage enactment pursuing the US FDA support of its archetypal medicine, REDEMPLO (plozasiran). This siRNA therapeutic, designed to dainty familial chylomicronemia syndrome/FCS, besides received regulatory clearances successful China and Canada.

The US motorboat has shown aboriginal momentum with implicit 100 archetypal prescriptions and the constitution of a dedicated diligent enactment program, marking a large milestone successful the company’s history. The company’s probe and improvement pipeline reached respective method landmarks, highlighted by the initiation of a Phase 1/2a proceedings for ARO-DIMER-PA, the industry’s archetypal dual-function objective campaigner to people 2 genes successful 1 molecule. Additionally, Arrowhead reported encouraging interim information from its obesity programs, wherever ARO-INHBE showed a important value nonaccomplishment vantage erstwhile combined with tirzepatide. The steadfast besides precocious its CNS efforts by dosing the archetypal subjects successful a proceedings for ARO-MAPT, which uses a caller transportation strategy susceptible of crossing the blood-brain barrier.

Jirsak/Shutterstock.com

Financially, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) swung to a nett income of $30.8 cardinal for the quarter, a crisp opposition to the $173.1 cardinal nonaccomplishment successful the anterior twelvemonth period. This profitability was driven by a surge successful gross to $264 million, fueled by a $200 cardinal upfront outgo from a caller planetary collaboration with Novartis and a $200 cardinal milestone from Sarepta Therapeutics.

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) develops medicines for the attraction of intractable diseases successful the US. Its pipeline chiefly includes Plozasiran, Zodasiran, ARO-DIMER-PA, and ARO-PNPLA3.

While we admit the imaginable of ARWR arsenic an investment, our condemnation lies successful the content that immoderate AI stocks clasp greater committedness for delivering higher returns and person constricted downside risk. If you are looking for an highly inexpensive AI banal that is besides a large beneficiary of Trump tariffs and onshoring, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey connected Google News.